Bupropion's Neurotransmitter Mechanisms
Bupropion acts primarily on dopamine and norepinephrine through inhibition of their reuptake, and additionally functions as an antagonist of nicotinic acetylcholine receptors.
Primary Mechanisms of Action
According to FDA labeling, bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, and does not inhibit monoamine oxidase or the reuptake of serotonin 1. This dual norepinephrine-dopamine reuptake inhibition represents the core mechanism, though the FDA acknowledges the precise mechanism remains incompletely understood 1.
The most recent guideline evidence (2025) confirms bupropion is a sympathomimetic drug that blocks neuronal uptake of dopamine and norepinephrine, thereby simulating some of the desirable effects of nicotine 2.
Secondary Mechanism: Nicotinic Receptor Antagonism
Beyond monoamine reuptake inhibition, bupropion also acts as an inhibitor of nicotinic acetylcholinergic receptors 3. This antagonistic activity at α4β2 nicotinic receptors may blunt the rewarding effects of nicotine from cigarettes, contributing to its efficacy in smoking cessation 2.
Research demonstrates bupropion competitively inhibits α3β2* and α3β4* nicotinic receptors in rat striatum and hippocampus at concentrations (IC₅₀ = 323 nM to 1.27 μM) that overlap with its transporter inhibition effects 4. This dual action on both transporters and nicotinic receptors likely explains its unique clinical profile for smoking cessation.
Neurotransmitter Effects in Practice
What Bupropion Does:
- Dopamine: Blocks reuptake, increasing synaptic availability
- Norepinephrine: Blocks reuptake, increasing synaptic availability
- Acetylcholine (nicotinic): Antagonizes nicotinic receptors
What Bupropion Does NOT Do:
Clinical Implications
This unique neurotransmitter profile explains bupropion's distinct clinical characteristics:
- Lower sexual dysfunction compared to SSRIs (due to lack of serotonergic activity)
- Efficacy in smoking cessation (nicotinic receptor antagonism combined with dopamine effects) 3, 2
- Potential benefit in depression with comorbid conditions where dopaminergic/noradrenergic activity is advantageous 3
- Lower risk of mania induction compared to serotonergic antidepressants 5
Important Caveat
While bupropion's primary actions are on dopamine, norepinephrine, and nicotinic receptors, research suggests it may have additional effects on serotonin type 3A receptors (5-HT3AR) as a negative allosteric modulator 6, though this is not part of its established FDA-recognized mechanism 1.